Real-world data on the relative contribution of clinical and pathologic characteristics to breast cancer-specific mortality, by breast cancer subtype according to HR and HER2 status, as well as the incidence of patients who meet the monarchE clinicopathologic high-risk criteria and their associated survival outcomes relative to those who do not fulfill the criteria, will assist in identifying those patients with EBC who stand to benefit most from therapy escalation. The gene discussed is ERBB2; the disease is breast carcinoma.